Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Cisplatin-based chemotherapy is the standard of care for patients with muscle invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Van Allen, Eliezer M., Mouw, Kent W., Kim, Philip, Iyer, Gopa, Wagle, Nikhil, Al-Ahmadie, Hikmat, Zhu, Cong, Ostrovnaya, Irina, Kryukov, Gregory V., O’Connor, Kevin W, Sfakianos, John, Garcia-Grossman, Ilana, Kim, Jaegil, Guancial, Elizabeth A., Bambury, Richard, Bahl, Samira, Gupta, Namrata, Farlow, Deborah, Qu, Angela, Signoretti, Sabina, Barletta, Justine A., Reuter, Victor, Boehm, Jesse, Lawrence, Michael, Getz, Gad, Kantoff, Philip, Bochner, Bernard H., Choueiri, Toni K., Bajorin, Dean F., Solit, David B., Gabriel, Stacey, D’Andrea, Alan, Garraway, Levi A., Rosenberg, Jonathan E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4238969/
https://ncbi.nlm.nih.gov/pubmed/25096233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0623
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi